drugset
drugset / Trial / NCT04499963

Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04499963 ↗

Phase 2 Completed 100 enrolled Richard Bedlack, M.D., Ph.D.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This will be a 6-month, widely inclusive, virtual, single-center, open-label pilot trial utilizing a historical control group.

Timeline

Start
2020-08-28
Primary completion
2022-08-30
Completion
2022-08-30

Outcome

Missed primary endpoint

registry analysis (superiority test); Open Label Arm; p = 0.984; t-test, 2 sided NCT04499963 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 90 mg —

Indications

amyotrophic lateral sclerosis